Zoetis Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Zoetis Inc. (ZTS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 78.29 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-02-12
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-12-31 was 47.75K shares.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-09-29 was 21.17K shares.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-06-30 was 25.89K shares.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2013-03-31 was 13.49K shares.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 78.29K shares, a 101.24% increase from fiscal 2024.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 38.90K shares, a 66.54% decline from fiscal 2023.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 116.27K shares, a 208.51% increase from fiscal 2022.
- Zoetis Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 37.69K shares, a 50.08% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 78.29K shares 10-K · filed 2026-02-12 | |||
| 2024-12-31 | 38.90K shares 10-K · filed 2025-02-13 | |||
| 2023-12-31 | 116.27K shares 10-K · filed 2024-02-13 | |||
| 2022-12-31 | 37.69K shares 10-K · filed 2023-02-14 | |||
| 2021-12-31 | 25.11K shares 10-K · filed 2022-02-15 | |||
| 2020-12-31 | 18.07K shares 10-K · filed 2021-02-16 | |||
| 2019-12-31 | 24.21K shares 10-K · filed 2020-02-13 | |||
| 2018-12-31 | 101.71K shares 10-K · filed 2019-02-14 | |||
| 2017-12-31 | 31.45K shares 10-K · filed 2018-02-15 | |||
| 2016-12-31 | 266.91K shares 10-K · filed 2017-02-16 | |||
| 2015-12-31 | 162.64K shares 10-K · filed 2016-02-24 | |||
| 2014-12-31 | 286.07K shares 10-K · filed 2015-02-27 | |||
| 2013-12-31 | 47.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | 68.93K shares derived: sum of 2 quarters · filed 2014-03-26 | 94.82K shares derived: sum of 3 quarters · filed 2014-03-26 | 108.31K shares 10-K · filed 2014-03-26 |
| 2013-09-29 | 21.17K shares derived: 10-K 12 month − 3 quarters · filed 2014-03-26 | 47.07K shares derived: sum of 2 quarters · filed 2014-03-26 | 60.56K shares 10-Q · filed 2013-11-13 | |
| 2013-06-30 | 25.89K shares 10-Q · filed 2013-08-14 | 39.38K shares derived: sum of 2 quarters · filed 2013-08-14 | ||
| 2013-03-31 | 13.49K shares 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |